This agreement, which follows extensive discussions with the European Commission in the context of the merger control review of INOVYN, is a key step towards completion of the INOVYN project, a joint venture for the development of chlorovinyls.

ICIG specialises in chemicals and pharmaceuticals, with 23 manufacturing sites across Europe and the United States. The assets being divested consist ofchlorine plants and EDC/ VCM plants in Tessenderlo, Belgium, PVC plants in France, the Netherlands and Germany and EDC plants in the UK.

In addition, the membrane chlorine plant at Runcorn is to be placed in a 50/ 50 joint venture between INOVYN and ICIG.